1. Home
  2. PLX

as of 11-18-2026 10:46am EST

$2.93
+$0.04
+1.21%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Founded: 1993 Country:
United States
United States
Employees: N/A City: HACKENSACK
Market Cap: 207.1M IPO Year: 1996
Target Price: $12.00 AVG Volume (30 days): 939.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.31 EPS Growth: -300.00
52 Week Low/High: $1.65 - $3.19 Next Earning Date: 11-10-2026
Revenue: $52,744,000 Revenue Growth: -1.23%
Revenue Growth (this year): 65.42% Revenue Growth (next year): -18.68%
P/E Ratio: 9.34 Index:
Free Cash Flow: -13631000.0 FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 10, 2026 · 100% conf.

AI Prediction BUY

1D

-0.32%

$2.84

Act: +9.27%

5D

+6.34%

$3.03

20D

+11.57%

$3.18

Price: $2.85 Prob +5D: 100% AUC: 1.000
0001104659-26-124761

EX-99.1

2 plx-ex99d1.htm

EX-99.1

Exhibit 99.1

‌​

​

Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. ET

●Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million for the same period in 2025

●Net income was $4.0 million for the third quarter, up from $2.4 million in the third quarter of 2025, and net income was $26.1 million for the nine months ended September 30, 2026

●Management expects to meet or exceed 2026 guidance for total revenues of approximately $78.0 million to $83.0 million

●The PRX-115 Phase 2 RELEASE study remains on track, aiming to improve adherence and durability of response in uncontrolled gout, a substantial unmet need; top-line results anticipated in the second half of 2027

●Cash, cash equivalents, and short-term bank deposits were $48.5 million as of September 30, 2026

CARMIEL, Israel, November 10, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the third quarter ended September 30, 2026, and provided a business and clinical update.

“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities,” said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics. “We end the quarter with cash and deposits of $48.5 million, a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout. Uncontrolled gout is a disease with low quality of life and high unmet need and represents a blockbuster uricase market opportunity. Current uricase therapy has challenges including infusion burden, immunogenicity with loss of efficacy, and safety concerns. We designed PRX-115 for reduced immunogenicity and less frequent dosing that could reduce infusion burden and improve patient adherence. We look forward to top-line results from the RELEASE study in the second half of 2027.”

Third Quarter 2026 Operational Update

Elfabrio® for Fabry Disease

●Elfabrio received marketing authorization in Brazil for both the every-two-weeks and the every-four-weeks dosing regimens. Chiesi Global Rare Diseases is the Company’s partner for the global development and commercialization of Elfabrio.

​

​

​

PRX-115 for uncontrolled gout

Phase 2 RELEASE Study

●Patient enrollment continues in the Company’s Phase 2 RELEASE study (NCT07280156) of PRX‑115, a recombinant PEGylated uricase, for the treatment of uncontrolled gout; anticipated top‑line results in the second half of 2027.

​

ACR 2026  Phase 1 Data

●The Company is presenting a poster at the American College of Rheumatology (ACR) Convergence 2026, which will be made available on the publications page of the Company’s website.

●The analysis being presented at ACR Convergence 2026 covers the 18 mg, 24 mg and 36 mg cohorts; there were six participants per cohort who received a single infusion and were followed for 85 days.

●The Company previously reported that higher single doses of PRX 115 lowered mean plasma uric acid for longer durations in participants with elevated plasma uric acid levels (ACR 2024).

●New individual patient data presented at ACR 2026 reinforce this finding and show the effect associated with PRX-115 plasma levels remaining measurable for up to 85 days.

●These data support the potential of PRX-115 to be a best-in-class uricase therapy with less frequent dosing.

​

Focus on Rare Renal Indications (Preclinical Programs)

●The Company continues to advance PRX‑119, its long‑acting DNase I program, as part of a broader strategic focus on rare renal indications, as well as other research collaborations.

​

Financial Outlook: Building Durable Growth and Long–Term Value

The Company has no outstanding debt or warrants.

​

Priorities remain consistent:

1.Support our commercial partners through the manufacture and supply of our products

2.Advance PRX–115 as a potential best–in–class therapy for patients with uncontrolled gout

3.Advance rare renal programs leveraging the Company’s R&D strengths

​

The Company reaffirms its 2026 revenue guidance and expects to meet or exceed these ranges:

●Total revenues of approximately $78.0 million to $83.0 million, including the $25.0 million milestone payment received from Chiesi in Q1 2026.

oFull-year 2026 revenues from sales of Elfabrio, excluding milestones, of approximately $33.0 million to $35.0 million.

oFull-year 2026 revenues from sales of Elelyso® of approximately $20.0 million to $23.0 million.

This outlook is not a guarantee of future performance, and stockholders should not rely on such forward-looking statements. These estimates ar

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 12, 2026 · 99% conf.

AI Prediction BUY

1D

-0.32%

$2.61

Act: -9.92%

5D

+6.33%

$2.79

20D

+11.54%

$2.92

Price: $2.62 Prob +5D: 100% AUC: 1.000
0001104659-26-094433

EX-99.1

2 plx-20260812xex99d1.htm

EX-99.1

​

​

Exhibit 99.1

​

​

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT

●Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio®

●Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone payment

●Year-to-date, the Company achieved profitability with a net income of $22.1 million

●The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue

●PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027

●Cash, cash equivalents, and short-term bank deposits were $40.7 million as of June 30, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115

CARMIEL, Israel, August 12, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.

During the second quarter, Protalix grew revenues from selling goods, driven primarily by continued penetration of Elfabrio® globally, advanced enrollment in the PRX-115 Phase 2 RELEASE clinical trial, and reaffirmed its strategic priorities and financial outlook for 2026.

"We enter the second half of 2026 in a position of strength, driven by the continued penetration and growth of Elfabrio® through our partnership with Chiesi, a trend toward achieving our financial goals for 2026," said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics. "Total revenue climbed to $53.6 million from $25.8 million for the same period in 2025. With $40.7 million in cash and short-term deposits, we are well-positioned to fund execution across our operations. We remain focused on continued enrollment in our PRX-115 Phase 2 RELEASE study and our pipeline addressing rare renal indications."

Second Quarter 2026 Operational Update

Elfabrio® for Fabry Disease

●On May 4, 2026, the U.S. Patent and Trademark Office (USPTO) issued a Patent Term Extension certificate for U.S. Patent No. 9,194,011, covering Elfabrio® (pegunigalsidase alfa-iwxj). The extension adds five years to the patent term, moving the U.S. expiration date to November 17, 2035.

●Elfabrio® received orphan drug designation and Marketing Authorization in South Korea in May 2026, with Kwangdong Pharmaceutical Co., Ltd. as the local marketing authorization holder.

​

PRX-115 for Uncontrolled Gout – RELEASE Phase 2 continues enrollment

●On July 7, 2026, the USPTO issued U.S. Patent No. 12,674,146, "Modified Uricase and Uses Thereof," to Protalix Ltd., strengthening the Company's intellectual property position around PRX-115.

●Patient enrollment continues in the Company’s RELEASE Phase 2 clinical trial (NCT07280156) of PRX‑115, a recombinant PEGylated uricase, for the treatment of uncontrolled gout.

●The Company continues to anticipate top‑line results in the second half of 2027.

​

Focus on Rare Renal Indications (Preclinical Programs)

●The Company continues to advance PRX‑119, its long‑acting DNase I program, as part of a broader strategic focus on rare renal indications, as well as other research collaborations.

​

Financial Outlook: Building Durable Growth and Long–Term Value

The Company operates a profitable growing commercial business through its partnerships, and a focused pipeline aligned to areas of high unmet need. The Company has a strong balance sheet, with no outstanding debt or warrants. The Company believes that its current business model limits downside risk while preserving significant upside potential as the Company progresses its clinical and preclinical programs, expands its commercial footprint, and pursues strategic partnerships to accelerate impact and scale.

​

Priorities remain consistent:

1.Support our commercial partners through the manufacture and supply of our products

2.Advance PRX–115 as a potential best–in–class therapy for patients with uncontrolled gout

3.Advance rare renal programs leveraging the Company’s R&D strengths

​

The Company reaffirms its previously stated 2026 revenue expectations:

●Total revenue in 2026 to range from approximately $78.0 million to $83.0 million including the $25.0 million milestone which the Company has received from Chiesi.

oFull‑year 2026 revenues from sales of Elfabrio® without milestones to range from approximately $33.0 million to $35.0 million.

oFull‑year 2026 revenues from sales of Elelyso® to range from appr

2026
Q1

Q1 2026 Earnings

8-K BUY

May 13, 2026 · 100% conf.

AI Prediction BUY

1D

-0.81%

$1.91

Act: +3.63%

5D

+6.62%

$2.06

Act: +4.15%

20D

+12.24%

$2.17

Act: +6.22%

Price: $1.93 Prob +5D: 100% AUC: 1.000
0001104659-26-059749

EX-99.1

2 plx-20260513xex99d1.htm

EX-99.1

​

​

Exhibit 99.1

​

​

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EDT

●Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every-4-weeks (E4W) dosing regimen; $25 million milestone received from Chiesi

●PRX-115 Phase 2 study continues to advance as planned with top-line results anticipated in the second half of 2027

●The Company reaffirms its previously stated 2026 revenue guidance of $78.0-$83.0 million including the $25.0 million milestone received from Chiesi

●Cash, cash equivalents, and short-term bank deposits were $51 million as of March 31, 2026, providing sufficient capital to fund ongoing operations including the Phase 2 RELEASE clinical trial of PRX-115

CARMIEL, Israel, May 13, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the first quarter ended March 31, 2026, and provided a business and clinical update.

During the first quarter, the Company continued to execute against its commercial partnerships, advance its clinical and preclinical development programs, and reaffirm its strategic priorities and financial outlook for 2026.

“Protalix entered 2026 with positive momentum,” said Dror Bashan, President and Chief Executive Officer of Protalix BioTherapeutics. “With the recent regulatory progress for Elfabrio in Europe, which triggered the $25 million milestone payment, the continued enrollment of our PRX-115 Phase 2 RELEASE study, and a growing focus on rare renal diseases, we believe the company is entering a pivotal period of growth and clinical advancement. We are confident in our strategy and reaffirm our guidance for 2026. We believe our business model positions us well to generate long-term value while advancing therapies that meaningfully address unmet needs.”

First Quarter 2026 Operational Update

Elfabrio® for Fabry Disease

●Protalix and its partner, Chiesi Farmaceutici, continue to support the launch and expansion of Elfabrio across approved markets.

●Following the previously announced European Commission approval of the 2 mg/kg every-4-weeks (E4W) dosing regimen, Protalix believes Elfabrio is well-positioned to reduce treatment burden for patients with Fabry disease in the European Union without compromising efficacy.

●The E4W option enhances Elfabrio’s competitive positioning in the European Union and supports broader adoption by providing increased dosing flexibility.

●The FDA-approved dosing regimen for Elfabrio in the United States remains 1 mg/kg every 2 weeks.

●With the global Fabry market projected to reach approximately $3 billion by 2031, Elfabrio® is positioned as a leading therapy with the potential to achieve a meaningful 15% to 20% global market share, supported by strong execution through Protalix’s partnership with Chiesi.

​

​

PRX-115 for Uncontrolled Gout – RELEASE Phase 2 continues enrollment

●The RELEASE Phase 2 clinical trial (NCT07280156) of PRX-115, a recombinant PEGylated uricase, for the treatment of uncontrolled gout continues to enroll patients.

●The Company continues to anticipate top-line results in the second half of 2027.

●PRX-115 is designed as a potential best-in-class, long-acting uricase therapy, which is supported by favorable Phase 1 data, with a possible E4W dosing schedule with or without an immunomodulator, or less frequent dosing with an immunomodulator, aiming to improve adherence and durability of response for patients with uncontrolled gout.

●By addressing immunogenicity challenges and enabling more flexible dosing intervals, the Company believes PRX-115 is well-positioned to capture a meaningful share of the uncontrolled gout segment, where even modest penetration represents significant commercial opportunity.

​

Focus on Rare Renal Indications (Preclinical Programs)

●The Company continues to advance PRX-119, its long-acting DNase I program, as part of a broader strategic focus on rare renal indications.

●The Company also continues to collaborate with Secarna to identify RNA-based therapeutic candidates that may complement its proprietary ProCellEx® platform.

​

Financial Outlook: Building Durable Growth and Long–Term Value

The Company operates a profitable growing commercial business through its partnerships, and a focused pipeline aligned to areas of high unmet need. The Company has a strong balance sheet, with no outstanding debt or warrants. The Company believes that its current business model limits downside risk while preserving significant upside potential as the Company progresses its clinical and preclinical programs, expands its commercial footprint, and pursues strategic partnerships to accelerate im

Share on Social Networks: